Fundamental Analysis of Champions Oncology Inc - Growth / Value Index
CSBR - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 5.00
Book Value in last 3 years is trending down
Book value is negative
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -3280.81 | -11929.77 | -9923.31 % | |
| Price to Book | -10304.04 | -2830.06 | -38780.48 % | -31045.03 |
| Price to Sales | -6869.51 | 1181.46 | 87081.77 % | |
| Enterprise Value to EBITDA Multiple | -5.70 | -12107.39 | -45762.47 % |
CSBR - Profitability Highlights
Profitability Analysis
During the past twelve months, the company has given a strong Net Margin of 209.38%
All key Trailing Twelve Months Margin growing by 15 %
Reasonable Dividend Yield of 3.26 %
Steady Growth in EPS for last four quarters
Tsr Profitability Index - Very Poor Score of 5.00
Company Net profit is Negative for last 5 Quarters
In the last three years, the company has given poor Net Margin
In the last three years, the company has given poor Returns on Assets
Negative Net Margin MRQ
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -417.94 | -115.08 | -2010.12 % | 0 |
| Return On Asset | -37.90 | -74.24 | -4892.92 % | -9.44 |
| Net Profit Margin | 209.38 | -9.90 | -987.50 % | -21.05 |
| Operating Profit Margin | 194.60 | -9.76 | -889.37 % | -21.44 |
| EBITDA Margin | 207.60 | -9.76 | -316.81 % | -21.44 |
Highlights
| Market Cap | 63890.86 K |
| Enterprise Value | 54980.86 K |
| Price/Book TTM | -10304.04 |
| Outstanding Share | 13593.80 K |
| Float/ Outstanding Share | 34.73% |
| Dividend Yield | 3.26 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 3.00 |
| Altman Z Score | -10.10 |
| Sloan Ratio | -0.895 |
| Peter Lynch Fair Value | 0 |
CSBR - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Tsr Growth Index - Very Poor Score of 13.88
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | -4646.00 K | 9.69 % | 3.85 % |
| Gross Profit | -48991.00 K | 120.63 % | 15.84 % |
| EBITDA | -9645.00 K | 337.83 % | 75.19 % |
| Net Profit | -9728.00 K | 1073.54 % | 22.16 % |
| EPS | -0.0014 | 101.02 % | NA |
CSBR - Stability Highlights
Stability Analysis
Altman Z Score of -10.12 suggest high risk
Interest Coverage of 0
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.261 | 124.87 % | -0.634 |
| Cash Ratio | 0.466 | -9.65 % | |
| Quick Ratio | 0.895 | 0 % | 0.601 |
| Shareholders Equity | 64.51 | 150.92 % | |
| Debt to EBITDA | -0.230 | -148.19 % |
Historical Valuation Ratios of Champions Oncology Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Champions Oncology Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Champions Oncology Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Champions Oncology Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)